Thyroid Cancer Diagnostics Market, By Product, By Type, By Technique, By End-User, By Country, and By Region – Global Industry Analysis, Market Size, Market Share & Forecast from 2025-2032

REPORT HIGHLIGHT

Thyroid Cancer Diagnostics Market size was valued at US$ 3,167.24 Million in 2024, expanding at a CAGR of 5.5% from 2025 to 2032.

The diagnosis of thyroid cancer encompasses a thorough array of tests aimed at identifying and verifying the existence of cancer in the thyroid gland. This process includes physical assessments, blood analyses, imaging methods, biopsy techniques, and molecular or genetic evaluations. Timely and precise diagnosis is crucial for formulating effective treatment strategies and management, greatly enhancing patient outcomes and long-term survival rates. Sophisticated diagnostic instruments are vital in facilitating the prompt detection and categorization of thyroid tumors, allowing for personalized and targeted treatment options.

Thyroid Cancer Diagnostics Market- Market Dynamics

The increasing prevalence of thyroid cancer is anticipated to drive the growth of the market.As the incidence of thyroid cancers continues to increase, there is a significant rise in the need for early and precise diagnostic solutions. This development is resulting in higher adoption of sophisticated imaging methods, molecular diagnostics, and minimally invasive biopsy techniques, all of which are crucial for effective disease identification, categorization, and treatment strategy formulation. Approximately 53,000 individuals in the United States are diagnosed with thyroid cancer annually. The treatment outcomes for the majority of thyroid cancers are quite favorable. Nevertheless, around 2,000 individuals succumb to the disease each year. Additionally, the rise in healthcare expenditures and screening initiatives presents a growth opportunity for the market. However, the high costs associated with advanced diagnostic tools pose a challenge to market expansion.

Thyroid Cancer Diagnostics Market- Key Insights

As per the analysis shared by our research analyst, the global market is estimated to grow annually at a CAGR of around 5.5% over the forecast period (2025-2032)
Based on Product segmentation, Instruments was predicted to show maximum market share in the year 2024
Based on Type segmentation, Papillary carcinoma was the leading Type in 2024
Based on Technique segmentation, the Imaging Technique was the leading Technique in 2024
Based on End-User segmentation, Hospitals were the leading Technique in 2024
Based on region, North America was the leading revenue generator in 2024

Thyroid Cancer Diagnostics Market- Segmentation Analysis:

The Global Thyroid Cancer Diagnostics Market is segmented based on Product, Type, Technique, End-User, and Region.
The market is segmented into three categories according to Product: Instruments, Kits, and consumables. Instruments are at the forefront of market growth. Instruments are the primary drivers of growth in the Thyroid Cancer Diagnostics market due to their essential function in facilitating accurate and efficient detection of thyroid malignancies. These devices, which encompass advanced imaging systems, molecular diagnostic tools, and biopsy equipment, are being increasingly utilized in clinical environments to improve diagnostic accuracy. Their capability to aid in early diagnosis and track disease progression has rendered them crucial in the management of thyroid cancer, thus propelling their demand in hospitals, diagnostic centers, and research laboratories.
The market is segmented into two categories according to Type: Papillary carcinoma, Follicular carcinoma, and others. Papillary carcinoma leads the growth of the market. It holds a significant share in the Thyroid Cancer Diagnostics market, representing the majority of diagnosed cases due to its high prevalence among all types of thyroid cancer. The increasing incidence of this subtype, especially among women and in areas with developed healthcare systems, has greatly fueled the demand for precise and early diagnostic solutions. This leadership underscores the necessity for ongoing improvements in diagnostic technologies specifically designed for papillary thyroid carcinoma.
The market is categorized into three segments based on Technique: Blood test, Imaging, Biopsy, and Other. The Imaging Technique is the primary driver of market growth. Imaging techniques significantly contribute to the expansion of the Thyroid Cancer Diagnostics market, propelled by their essential function in the early detection, diagnosis, and monitoring of thyroid nodules and cancers. Modalities such as ultrasound, computed tomography (CT), magnetic resonance imaging (MRI), and positron emission tomography (PET) are extensively employed due to their non-invasive characteristics and their capacity to deliver detailed anatomical and functional information. Among these modalities, ultrasound is the most frequently utilized technique for initial assessment.
The market is categorized into three segments based on End-User: Hospitals, Cancer diagnostic centers, Academic and research institutes, and others. Hospitals are at the forefront of market growth due to their extensive diagnostic infrastructure and access to cutting-edge medical technologies. As the primary facilities for cancer screening, diagnosis, and treatment, hospitals are equipped with imaging systems, molecular diagnostic tools, and biopsy equipment that are crucial for the precise detection of thyroid cancer. The increasing influx of patients, the presence of specialized healthcare professionals, and the adoption of multidisciplinary care approaches further enhance the demand for thyroid cancer diagnostics within hospital environments. Moreover, the rise in healthcare spending and advancements in hospital-based diagnostic capabilities are also contributing to the expansion of the market.

Thyroid Cancer Diagnostics Market- Geographical Insights

North America leads in market growth, primarily due to advancements in cancer diagnostic technologies. The region has a well-established healthcare infrastructure, extensive access to advanced imaging systems, and a strong uptake of molecular diagnostic tools such as next-generation sequencing (NGS) and PCR. In the United States alone, the estimated figures for new diagnoses and deaths stand at 1.9 million and 609,360, respectively. The application of existing cancer diagnostic methods, including positron emission tomography (PET), X-ray computed tomography (CT), and magnetic resonance spectroscopy (MRS), along with molecular diagnostic techniques, has facilitated early detection rates and plays a crucial role not only in the therapeutic management of cancer patients but also in the early identification of cancer itself. Europe ranks as the second-largest region for market growth, supported by high awareness, strong healthcare systems, and favorable policies.

Thyroid Cancer Diagnostics Market- Competitive Landscape:

The market for thyroid cancer diagnostics is marked by fierce competition among well-established diagnostic leaders, specialized biotechnology companies, and new startups. Firms are persistently innovating to improve diagnostic precision, shorten turnaround times, and broaden their geographical reach. Major players are allocating resources toward next-generation sequencing (NGS), AI-enhanced imaging, and molecular diagnostics to secure a competitive advantage. Prominent companies are also venturing into emerging markets such as Asia-Pacific, Latin America, and the Middle East to take advantage of the growing incidence of thyroid cancer and the increased investment in healthcare infrastructure.

Recent Developments:

Thermo Fisher Scientific has announced that its in vitro diagnostic test, Oncomine, has been granted approval by the US Food and Drug Administration (FDA) for use as a companion diagnostic in grade 2 IDH-mutant glioma.
August 3, 2021 – NorthStar Medical Radioisotopes, LLC, a worldwide leader in the innovation, production, and commercialization of radiopharmaceuticals utilized for medical imaging and therapeutic purposes, along with GE Healthcare, has today declared the establishment of an exclusive agreement for the manufacturing and distribution of iodine-123 (I-123) capsules within the United States.

SCOPE OF THE REPORT


The scope of this report covers the market by its major segments, which include as follows:

GLOBAL THYROID CANCER DIAGNOSTICS MARKET KEY PLAYERS- DETAILED COMPETITIVE INSIGHTS

Abbott Laboratories
F. Hoffmann‑La Roche Ltd (Roche Diagnostics)
Siemens Healthineers
Thermo Fisher Scientific
GE HealthCare
Bio‑Rad Laboratories
Agilent Technologies
Philips Healthcare
Illumina, Inc.
Daiichi Sankyo
Hologic, Inc.
Becton Dickinson
PerkinElmer, Inc.
Qiagen N.V.
Veracyte, Inc.
Exact Sciences
NeoGenomics
DiaSorin S.p.A.
Guardant Health
Myriad Genetics
Others

GLOBAL THYROID CANCER DIAGNOSTICS MARKET, BY PRODUCT- MARKET ANALYSIS, 2019 - 2032

Instruments
Kits & consumables

GLOBAL THYROID CANCER DIAGNOSTICS MARKET, BY TYPE- MARKET ANALYSIS, 2019 - 2032

Papillary carcinoma
Follicular carcinoma
Other

GLOBAL THYROID CANCER DIAGNOSTICS MARKET, BY TECHNIQUE- MARKET ANALYSIS, 2019 - 2032

Blood test
Imaging
Biopsy
Other

GLOBAL THYROID CANCER DIAGNOSTICS MARKET, BY END-USER- MARKET ANALYSIS, 2019 - 2032

Hospitals
Cancer diagnostic centers
Academic and research institutes
Other

GLOBAL THYROID CANCER DIAGNOSTICS MARKET, BY REGION- MARKET ANALYSIS, 2019 - 2032

North America
U.S.
Canada
Europe
Germany
UK
France
Italy
Spain
The Netherlands
Sweden
Russia
Poland
Rest of Europe
Asia Pacific
China
India
Japan
South Korea
Australia
Indonesia
Thailand
Philippines
Rest of APAC
Latin America
Brazil
Mexico
Argentina
Colombia
Rest of LATAM
The Middle East and Africa
Saudi Arabia
UAE
Israel
Turkey
Algeria
Egypt
Rest of MEA Show more